Deep single-cell immune- and signaling profiles predict therapy response in chronic myeloid leukemia within hours
Chronic myeloid leukemia (CML) is effectively treated with small molecule BCR::ABL1 tyrosine kinase inhibitors (TKIs) but as in all cancers, early identification of suboptimal responders and non-responders is a challenge. Through mass cytometry analysis of peripheral blood leukocytes collected on the first day of TKI treatment, we generated high-dimensional single-cell data from de novo chronic phase CML patients enrolled in two multicenter clinical trials (clinicaltrials.gov: NCT01725204 and NCT01061177). In leukocytes, dasatinib and nilotinib inhibited intracellular signaling within 1 or 3 h after first oral dose, respectively, and each TKI had a unique signaling signature reflecting its kinase specificity profile beyond BCR::ABL1. From these data, an immune and signaling profile was constructed for each patient that predicted the treatment response (BCR::ABL1 IS , %) during the first 12 months of treatment. The predictive features were drug specific: response to dasatinib was dominated by leukemic burden, neutrophil maturity (pSTAT3 Y705) and immune effector activity (pERK ½ in T- and NK cells), whereas response to nilotinib was driven by the intrinsic signaling states of CD34 + CD38 low CD25 + LSC-like cells (cleaved caspase-3, pCRKL Y207 and STAT3 [total and Y705]). These results show that single cell immune and signaling profiles measured within hours of first dose can predict 12-month treatment response, anticipating future optimization of kinase inhibitor treatment within days rather than months.
Authors
- Jesper Stentoft (ORCID: https://orcid.org/0009-0003-4969-1201)
- Monica Hellesøy (ORCID: https://orcid.org/0000-0002-0115-7427)
- Øystein Sefland (ORCID: https://orcid.org/0000-0002-7176-7597)
- Satu M. Mustjoki (ORCID: https://orcid.org/0000-0002-0816-8241)
- Ulla Olsson‐Strömberg
- Stein‐Erik Gullaksen (ORCID: https://orcid.org/0000-0002-8512-9297)
- Robert John Tibshirani (ORCID: https://orcid.org/0000-0003-0553-5090)
- Dominik Georg Friedrich Wolf (ORCID: https://orcid.org/0000-0002-4761-075X)
- Sylvia K. Plevritis (ORCID: https://orcid.org/0000-0003-2796-9180)
- Bjørn Tore Gjertsen (ORCID: https://orcid.org/0000-0001-9358-9704)
- Henrik Hjorth‐Hansen (ORCID: https://orcid.org/0000-0002-2670-5696)
- Johan Richter (ORCID: https://orcid.org/0000-0002-0374-6823)
- Tobias Gedde‐Dahl (ORCID: https://orcid.org/0000-0002-3037-5378)
- Mathias Brevik (ORCID: https://orcid.org/0009-0007-5947-6723)
- Erin Craig
Institutions
- Oslo University Hospital (NO)
- University of Helsinki (FI)
- Uppsala University Hospital (SE)
- Innsbruck Medical University (AT)
- University of Oslo (NO)
- Universität Innsbruck (AT)
- Norwegian University of Science and Technology (NO)
- University of Michigan (US)
- Helsinki University Hospital (FI)
- Haukeland University Hospital (NO)
- Aarhus University Hospital (DK)
- Comprehensive Cancer Center Vienna (AT)
- Tyrolean Cancer Research Institute (AT)
- Stanford Medicine (US)
- Skåne University Hospital (SE)
- Fonna Hospital Trust (NO)
- University of Bergen (NO)
- Stanford University (US)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1038/s41392-026-03070-z
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Norges Teknisk-Naturvitenskapelige Universitet
- Universitetet i Bergen